Picture [iito] Back into Ad 650x80px
Financing › Details

Platomics–SEVERAL: investment, 201908 investment €7-digit from undisclosed investors


Period Period 2019-08-06
Organisations Money taker Platomics GmbH
  Money source SEVERAL
Products Product genomic software tools
  Product 2 venture capital

Platomics GmbH. (8/6/19). "Press Release: 7-digit Investment in Future Technology Genetic Testing".

Medical diagnostics is undergoing a groundbreaking digital revolution and a visionary Austrian company is leading the way in personalized medicine. In concrete terms, Platomics is developing a digital platform for the analysis of genetic data. This enables the genetic blueprint to be deciphered and better understood.

The technical background

The sequencing of the human genome for personalized diagnosis generates huge amounts of data. In recent years, new sequencing technologies have made it relatively easy and fast to read these data. For the interpretation of the data, however, highly complex analysis procedures are necessary. Genetic tests are already standard in special application areas such as prenatal tests or cancer diagnosis. However, genetic testing is still too cost-intensive in everyday medical practice.

Why genetic testing?

If correctly interpreted, genetic tests can help to better understand the development of diseases and thus significantly improve diagnosis and therapy. The effects and side effects of drugs are also significantly influenced by the genetic blueprint. Dr. Albert Kriegner, CEO of Platomics, says that the broad application of genetic tests is therefore imminent: "We are undergoing medical, technological and regulatory upheaval. Groundbreaking findings will fundamentally change medical diagnostics in the coming years. Platomics is at the forefront of shaping this paradigm shift towards personalized medicine. Our vision is to make a genetic test as affordable and easy to obtain as a conventional blood test." Platomics is a spin-off of the renowned Austrian Institute of Technology, where Kriegner headed the Department of Bioinformatics.

The product in practice

Diagnostic laboratories of physicians and hospitals already use the platform for standardized and validated analysis of their genetic data. An exchange with genetic centers enables a practical implementation of the platform. Customers particularly appreciate the extraordinarily high precision, sensitivity and user-friendliness combined with maximum data security. In the end, the patient and the healthcare system benefit from tailor-made diagnostics, therapy and medication.

Next Steps

The investment will expand Platomics' activities in the core areas of regulatory compliance, big data analysis, artificial intelligence, data security, software development and bioinformatics.

Original message: APA-OTS or
[ ]

Record changed: 2020-01-06


Picture [iito] Fighting Customers 650x80px

More documents for Platomics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top